Do GLP-1 medications actually stop working over time?

What did @askdrtami actually say?

Dr. Tami covers two common patient experiences with GLP-1 medications: slow early weight loss and mid-treatment plateaus. She says weight loss may be minimal in the "first six to eight weeks" because doses start low. She also claims nausea can happen when patients forget to eat, and that getting "a minimum of eight hours" of sleep is necessary for continued weight loss. She wraps up with a specific physiological claim: cortisol starts rising around 4 a.m., which is why going to bed early enough to cycle through all five sleep stages matters.

The brand name stumbles, "Ozenpig," "Hermanjaro," and "Wigovii," are clearly verbal slips in a casual TikTok, not misinformation. The substance of her advice is worth examining more carefully than her pronunciation.

Does the science back this up?

Partially, yes. The slow early weight loss claim is well-supported. The sleep advice is directionally correct but the "eight hours minimum" framing overstates the evidence. The cortisol timing detail is real physiology, though it is more nuanced than presented here.

On the dosing ramp: the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) used a 16-week escalation period before reaching the 2.4 mg maintenance dose of semaglutide, precisely to reduce gastrointestinal side effects. Weight loss in early weeks is genuinely modest. That part checks out.

On sleep: research does connect poor sleep to weight loss resistance. Tasali et al. (2022, JAMA Internal Medicine) found that extending sleep in short sleepers reduced caloric intake by roughly 270 calories per day. But the study did not establish eight hours as a universal threshold. Sleep need is individual, and the evidence supports "adequate sleep" more than a specific number.

On cortisol timing: the cortisol awakening response (CAR) is a real phenomenon. Cortisol does begin rising in the early morning hours, typically peaking 20-30 minutes after waking (Stalder et al., 2016, Psychoneuroendocrinology). The 4 a.m. reference is a reasonable approximation for many people, though it varies with chronotype.

What did they get wrong (or right)?

The nausea-from-not-eating claim is where things get slippery. Dr. Tami says nausea "could be because you ate and eat enough or you forgot to eat completely." That second part, nausea from not eating, is not well-established in the GLP-1 literature. GLP-1 receptor agonists suppress appetite and slow gastric emptying. Nausea is most commonly reported after eating, not from skipping meals. Attributing nausea primarily to forgetting to eat could lead patients to override appropriate appetite suppression, which is counterproductive.

The eight-hour sleep minimum is also presented with more confidence than the data supports. It is accurate that poor sleep elevates ghrelin and disrupts leptin signaling (Spiegel et al., 2004, PLOS Medicine), but framing seven hours as inadequate is not something the current evidence justifies for all adults. The American Academy of Sleep Medicine recommends seven or more hours for adults, not eight as a floor.

What she got right: the plateau is real, protein prioritization has solid support in obesity medicine, and sleep genuinely matters for weight management. These are legitimate clinical talking points.

What should you actually know?

If you are on a GLP-1 medication and weight loss has stalled, the plateau is common and does not mean the medication stopped working. Dose escalation, behavioral factors, and metabolic adaptation all play roles. A plateau after several months may also reflect the body defending a new set point, something the STEP 5 trial (Garvey et al., 2022, Nature Medicine) documented in long-term semaglutide users.

Sleep is a legitimate lever. Disrupted sleep raises cortisol and ghrelin, both of which work against weight loss. But obsessing over hitting exactly eight hours may create anxiety that itself disrupts sleep. Aim for consistent, quality sleep rather than a fixed number.

On nausea: if you are experiencing persistent nausea on a GLP-1, talk to your prescriber. Do not self-diagnose it as a sign you forgot to eat. Common causes include eating too quickly, eating high-fat meals, or taking the medication on a full stomach.

• Dose ramp-up periods are intentional and typically last 16-20 weeks for semaglutide.
• Weight loss plateaus are documented in clinical trials, not just anecdotes.
• Sleep quality affects ghrelin and leptin, hormones directly tied to appetite regulation.
• The cortisol awakening response is real but varies significantly by individual chronotype.
• Nausea from GLP-1s is most commonly linked to eating behaviors, not skipping meals.